Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. Trinity Biotech plc develops, acquires, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, sexually transmitted diseases, blood coagulation, and autoimmune disorders. It also sells raw materials to the life sciences industry. In addition, the company offers point of care diagnostic tests, which are carried out in the presence of the patient, principally to diagnose the presence of HIV antibodies in the patient. Its customers include hospitals, clinical laboratories, commercial reference laboratories, and research institutions. The company sells its products through distributor partners, as well as directly in the United States, the United Kingdom, France, and Germany.

Kyorin, founded in 1923, already has affiliates and subsidiaries in Germany and the US. KYORIN Co., Ltd. is a Japan-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates in two business segments. The Pharmaceuticals segment is engaged in the manufacture, purchase and sale of pharmaceutical products, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the manufacture of clinical testing products, as well as the research of new drugs and candidate compounds. The Others segment is involved in the development and sale of cosmetics, as well as raw materials of medicines and cosmetics, the promotion of sales, the planning and production of advertisements, the sale of packaging materials, in addition to the provision of advisory services and the operational management of funds.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

MediciNova, Inc. company was founded in 2000 and is headquartered in San Diego, California. MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The company's development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which is in Phase II clinical trial for the treatment of acute exacerbations of asthma; and MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis. The company's other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed second Phase I clinical trial for the treatment of solid tumors; MN-305, which completed a Phase II/III clinical trial for the treatment of generalized anxiety disorder and a Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders.

ChemOvation offers contract drug discovery research and design services to pharmaceutical and biotechnology companies. ChemOvation has expertise in organic and medicinal chemistry, and drug discovery. ChemOvation also provides protein binding and compound solubility measurements for clients' metabolism research. ChemOvation's team of contractors is built around a core of organic chemists and technicians. Formed in 1999, the company merged with KuDOS Pharmaceuticals in 2000. ChemOvation dissolved those bonds in 2005 having spun off from KuDOS and is independent once again.

Ironwood Pharmaceuticals (formerly Microbia) is a drug developer that is busy testing the gastrointestinal drug candidates in its pipeline. The company is developing lead drug candidate linaclotide, which is undergoing trials in partnership with Forest Laboratories and other co-developers for the treatment of irritable bowel syndrome, abdominal pain, and chronic constipation. The company's Microbia biotechnology subsidiary harnesses microbes to produce specialty chemicals from renewable resources with applications the agriculture, chemical, and pharmaceutical industries. Ironwood Pharmaceuticals made a move to go public when it filed for an IPO in 2009.

Founded in 1997, Chicago-based Integrated Genomics specializes in research in microbial genomics, biochemistry, and gene expression. Our scientists have broad experience in both in silico and wet lab sequencing, research and development with more than 100 relevant publications in these areas. Integrated Genomics has particularly long-standing relationships and active research in the area of lactic acid bacteria and pathogenic microbes, as well as a broad customer base across industry, academic and government institutions.Integrated Genomics’ products and services are based on ERGO™, our web-based genome analysis platform. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data with publicly available information. Focused on microbial genomics, ERGO™ provides better and faster identification of gene function across all organisms.

Quick-Med Technologies, Inc. was founded in 1997 and is headquartered in Gainesville, Florida. Quick-Med Technologies, Inc., a life sciences company, develops technologies for the medical and consumer healthcare markets in the United States. Quick-Med Technologies's technologies under development include NIMBUS, a family of organic molecules or polymers that are bio-engineered to have antimicrobial, hemostatic, and other properties, which could be used in a range of medical device applications, including contact lenses, wound dressings, incontinence products, or disposable gloves; and Stay Fresh, a chemical formulation for textiles that provides a durable antimicrobial agent, which can be bonded to fibers or fabrics so as to retain the biocidal property through various launderings and is suitable for a range of applications, including apparel, sportswear, active wear, and work wear, as well as furnishings, such as linens, drapes, and towels. Its other technologies under development comprise NimbuDerm, a novel copolymer used as a persistent hand sanitizer; and MultiStat, a family of matrix metalloproteinase inhibitors that are used for the maintenance, healing, and repair of skin and eyes.

Impax Laboratories, Inc. company was founded in 1993 and is headquartered in Hayward, California. mpax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical. The Global Pharmaceuticals division develops, formulates, manufactures, and sells controlled release and specialty generic pharmaceutical products. This division offers generic prescription products directly to wholesalers and large retail drug chains; and generic over-the-counter and generic prescription products through unrelated third-party pharmaceutical entities. The Impax Pharmaceutical division develops proprietary brand pharmaceutical products that address central nervous system disorders, including Alzheimer's disease, attention deficit hyperactivity disorder, depression, epilepsy, migraines, multiple sclerosis, Parkinson's disease, and schizophrenia. As of March 10, 2009, the company marketed 70 generic pharmaceuticals representing dosage variations of 24 different pharmaceutical compounds through its Global Pharmaceuticals division, as well as 16 products representing dosage variations of 4 different pharmaceutical compounds through its alliance agreements partners. Impax Laboratories markets and sells its generic pharmaceutical prescription drug products in the continental United States of America and the Commonwealth of Puerto Rico. It has alliance agreements with Teva Pharmaceutical Industries, Ltd.; Wyeth; Schering-Plough Corporation; and DAVA Pharmaceuticals, Inc.

Millennium Pharmaceuticals wants to be "the" drug company for the new millennium. Its cancer drug Velcade is approved as a treatment for multiple myeloma (a type of blood cancer) and Mantle Cell Lymphoma (or MCL, an aggressive form of non-Hodgkin's lymphoma). The company has more than a dozen other candidates in the pipeline, most of them cancer-related. Millennium's oncology-focused sales force, in partnership with Johnson & Johnson subsidiary Ortho Biotech, sells the drug in the US; Ortho Biotech is responsible for sales in Europe and in other countries where Velcade is approved (except Japan, which is covered by Janssen). Takeda Pharmaceutical acquired Millennium Pharmaceuticals for $8.8 billion in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.